These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25666181)

  • 41. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of hit molecules targeting allosteric site of hepatitis C virus NS5B polymerase.
    Polamreddy P; Vishwakarma V; Arumugam P; Bheemanati R; Esram P; Mahto MK; Kacker P
    J Biomol Struct Dyn; 2020 Mar; 38(5):1448-1466. PubMed ID: 31007134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.
    Vandyck K; Cummings MD; Nyanguile O; Boutton CW; Vendeville S; McGowan D; Devogelaere B; Amssoms K; Last S; Rombauts K; Tahri A; Lory P; Hu L; Beauchamp DA; Simmen K; Raboisson P
    J Med Chem; 2009 Jul; 52(14):4099-102. PubMed ID: 19507864
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preparation and handling of hepatitis C viral proteins NS3 and NS5B for structural studies.
    Marco SD; Carfí A
    Methods Mol Biol; 2009; 510():111-24. PubMed ID: 19009257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.
    Das D; Hong J; Chen SH; Wang G; Beigelman L; Seiwert SD; Buckman BO
    Bioorg Med Chem; 2011 Aug; 19(16):4690-703. PubMed ID: 21798747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weak affinity chromatography for evaluation of stereoisomers in early drug discovery.
    Duong-Thi MD; Bergström M; Fex T; Svensson S; Ohlson S; Isaksson R
    J Biomol Screen; 2013 Jul; 18(6):748-55. PubMed ID: 23479356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using computational techniques.
    Polamreddy P; Vishwakarma V; Saxena P
    J Cell Biochem; 2018 Nov; 119(10):8574-8587. PubMed ID: 30058078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined Protein- and Ligand-Observed NMR Workflow to Screen Fragment Cocktails against Multiple Proteins: A Case Study Using Bromodomains.
    Johnson JA; Olson NM; Tooker MJ; Bur SK; Pomerantz WCK
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ligand and Target Discovery by Fragment-Based Screening in Human Cells.
    Parker CG; Galmozzi A; Wang Y; Correia BE; Sasaki K; Joslyn CM; Kim AS; Cavallaro CL; Lawrence RM; Johnson SR; Narvaiza I; Saez E; Cravatt BF
    Cell; 2017 Jan; 168(3):527-541.e29. PubMed ID: 28111073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a target identification approach using native mass spectrometry.
    Liu M; Van Voorhis WC; Quinn RJ
    Sci Rep; 2021 Jan; 11(1):2387. PubMed ID: 33504855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives.
    Ismail MA; Abou El Ella DA; Abouzid KA; Mahmoud AH
    Bioorg Med Chem; 2012 Apr; 20(7):2455-78. PubMed ID: 22386565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C-Terminal Auto-Regulatory Motif of Hepatitis C Virus NS5B Interacts with Human VAPB-MSP to Form a Dynamic Replication Complex.
    Gupta G; Song J
    PLoS One; 2016; 11(1):e0147278. PubMed ID: 26784321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery and development of hepatitis C virus NS5A replication complex inhibitors.
    Belema M; Lopez OD; Bender JA; Romine JL; St Laurent DR; Langley DR; Lemm JA; O'Boyle DR; Sun JH; Wang C; Fridell RA; Meanwell NA
    J Med Chem; 2014 Mar; 57(5):1643-72. PubMed ID: 24621191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure of hepatitis C virus polymerase in complex with primer-template RNA.
    Mosley RT; Edwards TE; Murakami E; Lam AM; Grice RL; Du J; Sofia MJ; Furman PA; Otto MJ
    J Virol; 2012 Jun; 86(12):6503-11. PubMed ID: 22496223
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
    Manjula S; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.